Edition:
India

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts


Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​.ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​. 

Company Quote

5.52
 --
18 Apr 2019